Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types

Targeted nano-drug delivery systems conjugated with specific ligands to target selective cell-surface receptors or transporters could enhance the efficacy of drug delivery and therapy. Transporters are expressed differentially on the cell-surface of different cell types, and also specific transporters are expressed at higher than normal levels in selective cell types under pathological conditions. They also play a key role in intestinal absorption, delivery via non-oral routes (e.g., pulmonary route and nasal route), and transfer across biological barriers (e.g., blood–brain barrier and blood–retinal barrier. As such, the cell-surface transporters represent ideal targets for nano-drug delivery systems to facilitate drug delivery to selective cell types under normal or pathological conditions and also to avoid off-target adverse side effects of the drugs. There is increasing evidence in recent years supporting the utility of cell-surface transporters in the field of nano-drug delivery to increase oral bioavailability, to improve transfer across the blood–brain barrier, and to enhance delivery of therapeutics in a cell-type selective manner in disease states. Here we provide a comprehensive review of recent advancements in this interesting and important area. We also highlight certain key aspects that need to be taken into account for optimal development of transporter-assisted nano-drug delivery systems.

[1]  C. Solans,et al.  Biotinylated polyurethane-urea nanoparticles for targeted theranostics in human hepatocellular carcinoma , 2015, Nano Research.

[2]  D. Munn,et al.  Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. , 2008, The Biochemical journal.

[3]  Laura M Ensign,et al.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Y. Byun,et al.  Anticoagulant efficacy of solid oral formulations containing a new heparin derivative. , 2010, Molecular pharmaceutics.

[5]  Robert Podolsky,et al.  Up-regulation of the amino acid transporter ATB(0,+) (SLC6A14) in carcinoma of the cervix. , 2006, Gynecologic oncology.

[6]  A. Sparreboom,et al.  Drug Transporters: Recent Advances and Therapeutic Applications , 2009 .

[7]  P. Sinko,et al.  Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Eric C. Holland,et al.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma , 2010, Nature Reviews Cancer.

[9]  Hoo-Kyun Choi,et al.  Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  V. Muzykantov,et al.  Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. , 2013, ACS nano.

[11]  Soldatenkov Va,et al.  DNA-Binding Properties of Poly(ADP-Ribose) Polymerase: A Target for Anti-Cancer Therapy , 2004 .

[12]  I. S. Wood,et al.  Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins , 2003, British Journal of Nutrition.

[13]  Xuxia Wang,et al.  A choline derivate-modified nanoprobe for glioma diagnosis using MRI , 2013, Scientific Reports.

[14]  M. Qiao,et al.  Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes , 2016 .

[15]  E. Landau,et al.  Biotinylated Cubosomes: A Versatile Tool for Active Targeting and Codelivery of Paclitaxel and a Fluorescein-Based Lipid Dye. , 2015, Langmuir : the ACS journal of surfaces and colloids.

[16]  Eiji Takeda,et al.  Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)* , 1998, The Journal of Biological Chemistry.

[17]  P. Caliceti,et al.  Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers. , 2009, Bioconjugate chemistry.

[18]  V. Ganapathy,et al.  Targeting the Sodium-Dependent Multivitamin Transporter (SMVT) for Improving the Oral Absorption Properties of a Retro-Inverso Tat Nonapeptide , 2001, Pharmaceutical Research.

[19]  R. Cecchelli,et al.  Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood–brain barrier , 2007, Journal of neurochemistry.

[20]  J. Rappoport,et al.  Focusing on clathrin-mediated endocytosis. , 2008, The Biochemical journal.

[21]  F. Luo,et al.  Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway , 2006, BMC Cancer.

[22]  Nuria Oliva,et al.  Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. , 2016, Nature materials.

[23]  W. Wooster,et al.  Crystal structure of , 2005 .

[24]  Chen Jiang,et al.  Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. , 2015, ACS applied materials & interfaces.

[25]  J. Weidner Drug delivery. , 2001, Drug discovery today.

[26]  Lin Zhu,et al.  Building Stable MMP2-Responsive Multifunctional Polymeric Micelles by an All-in-One Polymer-Lipid Conjugate for Tumor-Targeted Intracellular Drug Delivery. , 2017, ACS applied materials & interfaces.

[27]  Erik C. Dreaden,et al.  P-glycoprotein-dependent trafficking of nanoparticle-drug conjugates. , 2014, Small.

[28]  Mary E Napier,et al.  More effective nanomedicines through particle design. , 2011, Small.

[29]  Rongqin Huang,et al.  Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene Delivery , 2011, Advanced materials.

[30]  T. Xu,et al.  Targeting cancer cells with biotin-dendrimer conjugates. , 2009, European journal of medicinal chemistry.

[31]  S. Ren,et al.  Smart nanodevice combined tumor-specific vector with cellular microenvironment-triggered property for highly effective antiglioma therapy. , 2014, ACS nano.

[32]  V. Ganapathy,et al.  Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB0,+ to deliver chemotherapeutic agents for colon cancer therapy , 2017, Drug delivery.

[33]  Y. Sai,et al.  Acetyl‐L‐carnitine permeability across the blood–brain barrier and involvement of carnitine transporter OCTN2 , 2003, Biopharmaceutics & drug disposition.

[34]  Dong Yun Lee,et al.  Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Seung Woo Chung,et al.  Functional transformations of bile acid transporters induced by high-affinity macromolecules , 2014, Scientific reports.

[36]  Seung Woo Chung,et al.  Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. , 2014, Biomaterials.

[37]  M. Nurunnabi,et al.  Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Lucas Pelkmans,et al.  Local Actin Polymerization and Dynamin Recruitment in SV40-Induced Internalization of Caveolae , 2002, Science.

[39]  R. Barrett,et al.  XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters , 2004, Journal of Pharmacology and Experimental Therapeutics.

[40]  V. Ganapathy,et al.  Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. , 2000, Journal of pharmaceutical sciences.

[41]  Ajay Kumar,et al.  Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. , 2011, Anticancer research.

[42]  Lin Zhu,et al.  MMP2-Sensitive PEG-Lipid Copolymers: A New Type of Tumor-Targeted P-Glycoprotein Inhibitor. , 2016, ACS applied materials & interfaces.

[43]  Kinam Park,et al.  Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. , 2013, Advanced drug delivery reviews.

[44]  E. Everett,et al.  Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Geldenhuys,et al.  The blood-brain barrier choline transporter. , 2012, Central nervous system agents in medicinal chemistry.

[46]  V I L F M Y W P G D N S A C E H K Q R T,et al.  Amino Acid , 2020, Definitions.

[47]  Y. Kanai,et al.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.

[48]  C. Rebouche,et al.  Carnitine metabolism and its regulation in microorganisms and mammals. , 1998, Annual review of nutrition.

[49]  G. Booker,et al.  Mechanisms of Biotin Transport , 2015 .

[50]  Seung Woo Chung,et al.  Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Andrew Tsourkas,et al.  Effect of ligand density, receptor density, and nanoparticle size on cell targeting. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[52]  Robert Podolsky,et al.  Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. , 2005, Biochimica et biophysica acta.

[53]  Hao Wang,et al.  RETRACTED ARTICLE: Cu2ZnSnSe4 quantum dots with controllable size and quantum confinement effect , 2013, Journal of Nanoparticle Research.

[54]  M. Hediger,et al.  The sodium-dependent ascorbic acid transporter family SLC23. , 2013, Molecular aspects of medicine.

[55]  V. Kosma,et al.  Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice , 2017, International Journal of Gynecologic Cancer.

[56]  Paul R Lockman,et al.  3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. , 2005, Bioorganic & medicinal chemistry.

[57]  Srinath Palakurthi,et al.  Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro. , 2009, Anticancer research.

[58]  P. Diwan,et al.  β-Hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[59]  Xue Shen,et al.  Chemo-photodynamic combined gene therapy and dual-modal cancer imaging achieved by pH-responsive alginate/chitosan multilayer-modified magnetic mesoporous silica nanocomposites. , 2017, Biomaterials science.

[60]  Gaurav Sahay,et al.  Endocytosis of nanomedicines. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[61]  M. Merkx,et al.  Monitoring bile acid transport in single living cells using a genetically encoded Förster resonance energy transfer sensor , 2013, Hepatology.

[62]  Ho-Chul Shin,et al.  Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent , 2001, Circulation.

[63]  I. Khalil,et al.  Uptake Pathways and Subsequent Intracellular Trafficking in Nonviral Gene Delivery , 2006, Pharmacological Reviews.

[64]  S. Mitragotri,et al.  Vascular Targeting of Nanocarriers: Perplexing Aspects of the Seemingly Straightforward Paradigm , 2014, ACS nano.

[65]  D. S. Lee,et al.  Synthesis and evaluation of biotin-conjugated pH-responsive polymeric micelles as drug carriers. , 2012, International journal of pharmaceutics.

[66]  V. Ganapathy,et al.  Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[67]  P. Dawson,et al.  Bile acid transporters , 2009, Journal of Lipid Research.

[68]  Jia Li,et al.  ATB0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes. , 2017, Biomaterials science.

[69]  A. Lamprecht,et al.  Drug delivery strategies for the treatment of malignant gliomas. , 2012, International journal of pharmaceutics.

[70]  Lin Zhu,et al.  Improving Tumor Specificity and Anticancer Activity of Dasatinib by Dual-Targeted Polymeric Micelles. , 2017, ACS applied materials & interfaces.

[71]  G. Wang,et al.  Cotransporting Ion is a Trigger for Cellular Endocytosis of Transporter‐Targeting Nanoparticles: A Case Study of High‐Efficiency SLC22A5 (OCTN2)‐Mediated Carnitine‐Conjugated Nanoparticles for Oral Delivery of Therapeutic Drugs , 2017, Advanced healthcare materials.

[72]  Peter Oelkers,et al.  Bile acid transporters , 1995, Current opinion in lipidology.

[73]  C. Alexander,et al.  Uptake and transport of B12-conjugated nanoparticles in airway epithelium , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[74]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[75]  Y. Byun,et al.  A new drug carrier, Nα-deoxycholyl-l-lysyl-methylester, for enhancing insulin absorption in the intestine , 2005, Diabetologia.

[76]  P. Mishra,et al.  Biotinylated methotrexate loaded erythrocytes for enhanced liver uptake. 'A study on the rat'. , 2002, International journal of pharmaceutics.

[77]  A. Hofmann,et al.  Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics , 2008, Cellular and Molecular Life Sciences.

[78]  J. Nezu,et al.  Functional relevance of carnitine transporter OCTN2 to brain distribution of l‐carnitine and acetyl‐l‐carnitine across the blood–brain barrier , 2001, Journal of neurochemistry.

[79]  F. Du,et al.  Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles. , 2014, Journal of pharmaceutical sciences.

[80]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[81]  Dong Yun Lee,et al.  Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[82]  S. Bröer,et al.  Involvement of OCTN2 and B0,+ in the transport of carnitine through an in vitro model of the blood–brain barrier , 2004, Journal of neurochemistry.

[83]  J. Nezu,et al.  Molecular and Functional Identification of Sodium Ion-dependent, High Affinity Human Carnitine Transporter OCTN2* , 1998, The Journal of Biological Chemistry.

[84]  Dong Yun Lee,et al.  Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates. , 2005, Bioconjugate chemistry.

[85]  Qiang Zhang,et al.  Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting , 2012, International journal of nanomedicine.

[86]  W. Pardridge Blood-brain barrier drug targeting: the future of brain drug development. , 2003, Molecular interventions.

[87]  M. Scalise,et al.  OCTN Cation Transporters in Health and Disease , 2013, Journal of biomolecular screening.

[88]  T. Minko,et al.  Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells , 2002, Cancer Chemotherapy and Pharmacology.

[89]  Y. Byun,et al.  Design, Synthesis, and Therapeutic Evaluation of Poly(acrylic acid)-tetraDOCA Conjugate as a Bile Acid Transporter Inhibitor. , 2015, Bioconjugate chemistry.

[90]  N. Vaziri,et al.  Biotin uptake by human proximal tubular epithelial cells: cellular and molecular aspects. , 2005, American journal of physiology. Renal physiology.

[91]  A. Fakhari,et al.  Controlling ligand surface density optimizes nanoparticle binding to ICAM-1. , 2011, Journal of pharmaceutical sciences.

[92]  Chen Jiang,et al.  Choline transporter-targeting and co-delivery system for glioma therapy. , 2013, Biomaterials.

[93]  Yu Zhang,et al.  Preparation, Characterization of 2-Deoxy-D-Glucose Functionalized Dimercaptosuccinic Acid-Coated Maghemite Nanoparticles for Targeting Tumor Cells , 2011, Pharmaceutical Research.

[94]  P. Lockman,et al.  The blood-brain barrier choline transporter as a brain drug delivery vector. , 2003, Life sciences.

[95]  J. Rautio,et al.  LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier? , 2013, Therapeutic delivery.

[96]  P. Dawson Bile Formation and the Enterohepatic Circulation , 2012 .

[97]  F. Du,et al.  Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. , 2014, Biomaterials.

[98]  Jin Sun,et al.  Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[99]  Wei He,et al.  Biotinylated liposomes as potential carriers for the oral delivery of insulin. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[100]  S. Cang,et al.  INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer , 2017, Gene Therapy.

[101]  M. Fromm,et al.  Transporter‐Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.

[102]  Ashish Jain,et al.  Phenylalanine-coupled solid lipid nanoparticles for brain tumor targeting , 2013, Journal of Nanoparticle Research.

[103]  P. Dawson,et al.  The organic solute transporter α-β, Ostα-Ostβ, is essential for intestinal bile acid transport and homeostasis , 2008, Proceedings of the National Academy of Sciences.

[104]  S. Iwata,et al.  Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT , 2011, Nature.

[105]  G. Wang,et al.  L-Carnitine-conjugated nanoparticles to promote permeation across blood–brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2 , 2017, Artificial cells, nanomedicine, and biotechnology.

[106]  Amino Acid Transporter , 2020, Definitions.

[107]  Sagar Agarwal,et al.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain , 2011, Expert Reviews in Molecular Medicine.

[108]  Zhonggui He,et al.  The endocytosis and intracellular fate of nanomedicines: Implication for rational design , 2013 .

[109]  Jinhua Dong,et al.  Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs. , 2017, Journal of medicinal chemistry.

[110]  Huan Wang,et al.  Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. , 2015, International journal of pharmaceutics.

[111]  Jin Sun,et al.  Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting. , 2016, Colloids and surfaces. B, Biointerfaces.

[112]  Y. Bhutia,et al.  The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy , 2014 .

[113]  Kwangmeyung Kim,et al.  Prevention effect of orally active heparin conjugate on cancer-associated thrombosis. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[114]  N. Gu,et al.  Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-D-g1ucose modified SPIOs. , 2012, European journal of radiology.

[115]  V. Ganapathy,et al.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. , 1998, Biochemical and biophysical research communications.

[116]  Y. Bhutia,et al.  SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. , 2016, The Biochemical journal.

[117]  V. Rotello,et al.  Insulin-Based Regulation of Glucose-functionalized Nanoparticle Uptake in Muscle Cells. , 2014, Journal of materials chemistry. B.

[118]  I. Tamai Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). , 2013, Biopharmaceutics & drug disposition.

[119]  V. Ganapathy,et al.  Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[120]  Patrice D Cani,et al.  Targeted nanoparticles with novel non-peptidic ligands for oral delivery. , 2013, Advanced drug delivery reviews.